omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study
by
Zanarini MC, Frankenburg FR.
Laboratory for the Study of Adult Development,
McLean Hospital, Belmont, MA 02478, USA.
zanarini@mclean.harvard.edu
Am J Psychiatry 2003 Jan;160(1):167-9

ABSTRACT

OBJECTIVE: The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder. METHOD: The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder. RESULTS: Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given placebo. Ninety percent of those in both groups completed all 8 weeks of the trial. Analyses that used random-effects regression modeling and controlled for baseline severity showed E-EPA to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms. CONCLUSIONS: The results of this study suggest that E-EPA may be a safe and effective form of monotherapy for women with moderately severe borderline personality disorder.

BPD
Essential fatty acids
Evolution and emotion
The evolution of suicide
Shakespearean suicides
Omega-3 plus antidepressant
Alcohol, suicide and serotonin
How stress triggers depression
Suicide, serotonin and dopamine
Omega-3 fatty acids in bipolar disorder
Depression and polyunsaturated fatty acids
Ethyl-eicosapentaenoate as an antidepressant
Unsaturated fatty acid deficiency and dopamine

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family